Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million) Unsecured Loan Financing | 67 | GlobeNewswire (Europe) | TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the "Company" or "MEDIROM"), today announced that it... ► Artikel lesen | |
Do | MEDIROM Healthcare Technologies Inc.: MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million) | 2 | GlobeNewswire (USA) | ||
Do | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
04.03. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
MEDIROM HEALTHCARE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
18.02. | MEDIROM Healthcare sees FY24 revenue to be about JPY8.2B | 1 | Seeking Alpha | ||
18.02. | MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited Financial Results for Full Year 2024 Under Japanese GAAP | 103 | GlobeNewswire (Europe) | NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the "Company"), today announced its preliminary, unaudited... ► Artikel lesen | |
18.02. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
29.01. | MEDIROM Healthcare Technologies Inc. Announces December 2024 Key Performance Indicators (KPIs) | 1 | GlobeNewswire (USA) | ||
29.01. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
21.01. | MEDIROM Healthcare Technologies Inc.: Completion of Offering and Increase in Registered Capital | 11 | GlobeNewswire (USA) | ||
21.01. | MEDIROM Healthcare Technologies Inc.: MEDIROM MOTHER Labs Provides MOTHER Bracelet? Device and Remote Health Monitoring System, REMONY, to TOPPAN Inc. | 6 | GlobeNewswire (USA) | ||
21.01. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
23.12.24 | MEDIROM verzeichnet moderates Wachstum bei November-KPIs | 1 | Investing.com Deutsch | ||
23.12.24 | MEDIROM reports modest growth in November KPIs | 1 | Investing.com | ||
23.12.24 | MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators (KPIs) | 2 | GlobeNewswire (USA) | ||
23.12.24 | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
13.12.24 | MEDIROM Healthcare Technologies Inc.: MEDIROM Healthcare Technology's Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round | 4 | GlobeNewswire (USA) | ||
13.12.24 | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
11.12.24 | MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering | 2 | GlobeNewswire (USA) | ||
11.12.24 | MEDIROM Healthcare Technologies Inc.: Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,115 | -2,70 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,658 | -0,15 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
PING AN HEALTHCARE | 0,890 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports First Full-Year Profit in 2024 | Synergies Between Health Care and Insurance Drive Scalable GrowthAI Innovations Fuel Continued Success
SHANGHAI and HONG KONG, March 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,022 | +21,11 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,424 | +3,92 % | Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance | The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/... ► Artikel lesen | |
CYTOSORBENTS | 1,054 | +3,54 % | CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue | Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor... ► Artikel lesen | |
VERU | 0,460 | +4,59 % | VERU INC. - 8-K, Current Report | ||
TEMPEST THERAPEUTICS | 0,794 | +2,85 % | Tempest Therapeutics: FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) | BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
VOLITIONRX | 0,552 | 0,00 % | VolitionRx erweitert Krebstest-Vereinbarung mit Fujifilm Vet Systems | ||
EKSO BIONICS | 0,442 | +9,68 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
IMUNON | 0,785 | -1,26 % | Imunon, Inc.: IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study | IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in... ► Artikel lesen | |
BEYOND AIR | 0,270 | +4,65 % | Beyond Air-Direktor Robert Carey kauft Stammaktien im Wert von 250.050 US-Dollar | ||
AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
NOVACYT | 0,570 | -1,04 % | Novacyt S.A. - Update re. Lab 21 HSE Prosecution | ||
AROVELLA THERAPEUTICS | 0,052 | -1,89 % | XFRA E4NA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |